ANGLE PLC (LON:AGL)

ANGLE PLC (LON:AGL)


Share Price
71.00 p
Change
2.5 (3.65 %)
Market Cap
£122.66 m
Proactive Investors - Run By Investors For Investors

ANGLE PLC

ANGLE PLC develops products for use in rare cell diagnostics that enable early, accurate identification of an individual’s condition for the prevention, treatment, and monitoring of disease.

EPIC: AGL
Market: AIM:AGL
52-week High/Low: 79.80p / 38.00p
Sector: Pharma & Biotech
Market Cap: £122.66 m
Website: www.angleplc.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of ANGLE PLC


ANGLE PLC Snapshot

ANGLE has a clear strategy to commercialise its Parsortix™ technology.

The cell capture and harvesting technology consists of a cell separation cassette together with an automated system to run blood samples through the cassette. There is extensive intellectual property protection around key elements of the system.

Successful evaluation of the system by major cancer research centres has already been achieved and a major part of ANGLE’s current efforts relate to further deployment with key opinion leaders in the field.

Regulatory authorization for the clinical use of the system is currently CE Marked while the process of FDA clearance has been initiated and is currently ongoing in the USA.

Widespread adoption of the Parsortix™ system in the clinical market is crucially dependent upon how information about the product is presented to key opinion leaders. In order to reach this goal, we aim to:
 

  • Undertake pilot studies assessing clinical applications for CTCs. Select the most promising applications
  • Undertake larger patient studies providing fully documented evidence of how the system should be used for particular patient applications in routine treatment
  • Convert key opinion leader support and peer reviewed publications into widespread adoption of the Parsortix™ system in routine patient care

How it Works

  • A liquid biopsy (blood sample) is taken from the patient
  • A disposable microscope slide sized cassette captures and harvests CTCs from the sample, based on the cells size and compressibility
  • A step-based reverse flow system allows the easy harvest of viable cells for analysis
  • Once captured and analysed, cells have the potential to be used to inform clinicians about the patient’s condition and most appropriate treatment protocol.
 

Competitive Advantages

  • Epitope-independent approach that does not depend on the use of antibodies
  • Very sensitive and specific
  • Captures clinically relevant cancer cells, including mesenchymal CTCs, which are involved in metastasis
  • Allows easy harvest of CTCs, providing a concentrated sample of viable cells for analysis
  • Low cost, small environmental footprint and is very easy to use

 

Introduction to the Parsotix Technology

 

Benefits of the Parsotix System

 

UK, North America & Canada.

Garth Selvey Non Executive Chairman


Garth Selvey has a BSc in Physics and Electronics Engineering from the University of Manchester and has spent thirty six years in the computer industry with technical, product, sales and marketing roles. He became Managing Director of TIS Applications Ltd in 1984 and a main board director of TIS Ltd prior to its acquisition by Misys in 1989.
He organised the management buyout of the social housing division of Misys and became Group Chief Executive of Comino Group plc when it floated on AIM in 1997. Comino moved to a full listing in 1999 where he remained until its successful public sale to Civica plc in February 2006. Garth joined ANGLE as a Non-executive Director in September 2006.

Andrew Newland Chief Executive

Andrew Newland is the founder and Chief Executive of ANGLE plc. For over twenty five years, he has specialised in building technology-based businesses based on strong intellectual property and for the last fifteen years he has been Chairman or on the Board of several specialist medical technology companies. Andrew has an MA in Engineering Science from the University of Cambridge, and is a qualified Chartered Accountant.
After working with the engineering conglomerate, TI plc, he worked for KPMG from 1982 to 1994; from 1985 to 1987 he was based in the US as a manager providing corporate finance and business advice to high technology firms in the area around Route 128, Boston, Massachusetts. During this time, he led KPMG’s involvement in the IPO of the medical technology company Cardio Data Inc. From 1987 to 1994 he worked for KPMG in the UK with responsibility for establishing KPMG’s UK and European High Technology Practices and High Technology Consulting Group. Andrew founded ANGLE in 1994. Together with ANGLE’s senior management team, Andrew has co-founded and led eleven technology companies in partnership with world class research organisations, both in the UK and the US. Andrew has been instrumental in developing and then delivering the business proposition for these companies, building management teams, raising finance and securing revenues. In 1999, Andrew led the team that founded the medical diagnostic company, Acolyte Biomedica. Acolyte was the first ever spin-out of dstl Porton Down, which specialised in rapid diagnosis of MRSA the ‘hospital super-bug’. Andrew chaired the company for several years and successfully led the company through three major rounds of venture capital investment. Andrew also founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nutrition research institute. Andrew chaired the Board of Provexis, a specialist nutraceutical company with a heart-health product, through to its successful flotation in 2005.

Ian Griffiths Finance Director

Ian Griffiths is the Finance Director of ANGLE plc. He has specialised in technology commercialisation for over twenty years and is an expert on the development and growth of new technology based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy, then in management consulting within KPMG’s High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work.
He joined ANGLE in 1995. As well as leading the finance function at ANGLE plc, he has been closely involved with the development and delivery of the UK, US and Middle East Consulting and Management businesses and in developing new Ventures, both third party and ANGLE’s own. Ian has been heavily involved in the start-up phase and also the ongoing development of ANGLE’s own ventures by working closely with management on business plans, financial and operational management, fund raising and commercial aspects, including both medical and physical sciences companies. He is currently leading the financial development of ANGLE’s major medical diagnostic business Parsortix.

Brian Howlett Non Executive Director

Brian Howlett has a wealth of international experience as a medtech leader which he is currently applying in a Non-Executive / Chairman capacity for surgical graft company Vascular Flow Technologies Ltd, skin cancer imaging company Michelson Diagnostics Ltd and medical device coating and surface modification company Accentus Medical Ltd, as well as ANGLE plc. Brian was formerly CEO of Lombard Medical Technologies PLC, an AIM listed company specialising in stents for abdominal aortic aneurysms from 2005 to 2009.
During his tenure significant capital was raised to fund the development of operations to commercialise the Aorfix stent graft towards regulatory approvals and growing revenues in EU, USA, Russia and Brazil. Corporate experience includes six years as UK Country Leader of Boston Scientific Ltd, between 1999 and 2005, during which time major medical devices such as the TAXUS drug eluting stent were launched driving sales and profits to the point where the UK and Ireland subsidiary became one of the leading revenue contributors to the Corporation’s European operations. Between 1987 and 1999, Brian was Managing Director of the UK sales and manufacturing subsidiary of Cobe Laboratories Inc. In addition, Brian spent almost 20 years in the pharmaceutical industry, gaining strong sales and marketing experience through a number of senior management positions in UK, Scandinavia and the Benelux markets within Fisons plc. Brian joined ANGLE as a Non-executive Director in January 2013.
 

Dr Jan Groen Non Executive Director

Dr Jan Groen is currently the Chief Executive Officer of MDxHealth, a genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in urological cancers. MDxHealth’s genomic tests are setting new standards in prostate and bladder cancer diagnosis, where they have helped over 100,000 patients avoid unnecessary diagnostic procedures.
His career spans over 25 years in clinical diagnostics and life science global markets. Dr. Groen was previously the President and COO of Agendia, responsible for their United States and European diagnostic operations, respectively. Dr. Groen is (co)-founder of ViroClinics and DxOrange and has held numerous management and scientific positions at Focus Diagnostics, a subsidiary of Quest Diagnostics, the Erasmus Medical Center, and Akzo-Nobel. He has had board mandates in several diagnostic companies. Currently he serves on the board of SPL Medical in the Netherlands. He holds a Ph.D. degree in Medical Microbiology from the Erasmus University Rotterdam, a BSc in Clinical Laboratory Studies and has published more than 125 papers in international scientific journals in the field of clinical diagnostics.

 

Significant Shareholders

The following shareholders amount to 3% or more of the ordinary share capital of the company.

Shares in issue: 143,486,522 10p Ords

 
Significant Shareholders (>3%) Date Amount Holding %
Jupiter Asset Management Limited 13/11/2018 20,080,840 13.99%
Dermot Keane 08/11/2018 12,777,088 8.90%
Legal & General 08/11/2018 10,093,439 7.03%
Fidelity International Limited 08/11/2018 8,944,382 6.23%
Andrew Newland 08/11/2018 7,054,686 4.92%

 

UK Office
10 Nugent Road,
The Surrey Research Park,
Guildford,
Surrey,
GU2 7AF,
United Kingdom

[email protected]
[email protected]
[email protected]

+44 (0)1483 343434

North America Office
1150 1st Ave,
Suite 1010,
King of Prussia, PA 19406

[email protected]
[email protected]
[email protected]
+1 610 233 4712

ANGLE Biosciences
50 Ronson Drive, Suite 105,
Toronto, Ontario, M9W 1B3,
Canada

416 798 1625

 

 

 

 

 

 

 

 

 

 

RSM UK Audit LLP
Portland

25 High Street

Crawley

West Sussex RH10 1BG

T +44 (0)845 057 0700

Bankers

NatWest Bank

PO Box 1 2nd Floor,

G3 2 Cathedral Hill

Guildford

Surrey

GU1 3ZR T

+44 (0)1483 739540 

Solicitors / Lawyers

Pinsent Masons

30 Crown Place

Earl Street

London

EC2A 4ES T

+44 (0)207 418 7000 

Financial Public Relations

F T I Consulting

200 Aldersgate

London

EC1A 4HD

T +44 (0)20 3727 1390 

Registrars Registrar

Link Asset Services
The Registry
34 Beckenham Road
Beckenham
Kent BR3 4TU
T +44 (0)871 664 0300
(Calls cost 10p per minute plus

 

Nominated Advisor & Broker

finnCap Ltd

60 New Broad Street

London EC2M 1JJ

T +44 (0)20 7220 050

 

Joint Broker

WG Partners LLP

85 Gresham Street

London EC2V 7NQ

+44 (0)203 705 9316

Columns Including AGL

VIEW ALL

Market Reports Including AGL

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use